Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment:A case report  

作　　者：Sang Jae Lee Si-Youn Song Min Kyoung Kim Hyung Gyun Na Chang Hoon Bae Yong-Dae Kim Yoon Seok Choi 

机构地区：[1]Department of Otorhinolaryngology-Head and Neck Surgery,College of Medicine,Yeungnam University,Daegu 42415,South Korea [2]Division of Hematology-Oncology,Department of Internal Medicine,College of Medicine,Yeungnam University,Daegu 42415,South Korea [3]Regional Center for Respiratory Diseases,Yeungnam University Medical Center,Daegu 42415,South Korea

出　　处：《World Journal of Clinical Cases》2023年第27期6664-6669,共6页世界临床病例杂志

基　　金：Supported by the 2023 Yeungnam University Research Grant.

摘　　要：BACKGROUND Anaplastic thyroid cancer(ATC)is a rare but aggressive type of thyroid carcinoma.BRAF V600E-mutation,which is found in 10%-50%of ATCs,is associated with poor prognosis.A recent clinical trial reported a substantial clinical benefit of concomitant treatment of dabrafenib(BRAF inhibitor)and trametinib(MEK inhibitor)for treating BRAF V600E-mutant ATC.However,reports on patients with ATC treated with this regimen following surgery are lacking.CASE SUMMARY We report the case of a 63-year-old female patient diagnosed with BRAF V600Emutant ATC.Following three surgeries—total thyroidectomy,total laryngectomy,and neck dissection—she was diagnosed with lung metastasis during follow-up.The metastatic ATC was successfully treated with dabrafenib and trametinib.The patient achieved a complete response at the 32-mo follow-up.CONCLUSION Adjuvant chemotherapy with dabrafenib plus trametinib is efficacious for treatment and prevention of recurrent ATC with BRAF mutation following surgery.

关 键 词：Thyroid carcinoma ANAPLASTIC BRAF Dabrafenib Trametinib Chemotherapy ADJUVANT Case report 

分 类 号：R818.8[医药卫生—放射医学]